Jasper Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Jasper Therapeutics şirketinin kazançları yıllık ortalama -20.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 33.8% oranında arttı.

Anahtar bilgiler

-20.80%

Kazanç büyüme oranı

52.82%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.04%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-1,639.24%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2026

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Analiz Makalesi • Jan 08

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • May 30

Here's Why Jasper Therapeutics (NASDAQ:JSPR) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jan 04

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Nov 18

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Summary Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large, underserved markets. Despite positive preliminary clinical results, Jasper faces financial risks, needing additional funds by Q3 2025, which may lead to shareholder dilution. Analysts rate JSPR as a strong buy with a $69.5 target, but caution is advised due to the speculative nature and financial instability. Investors should monitor upcoming clinical trial results for Briquilimab in January 2025, which could significantly impact Jasper's stock performance and future prospects. Read the full article on Seeking Alpha

Analiz Makalesi • Aug 30

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jan 23

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Jul 31

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Feb 02

Gelir ve Gider Dağılımı

Jasper Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:JSPR Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 26	-56	20	51
31 Dec 25	-76	20	61
30 Sep 25	-91	21	70
30 Jun 25	-91	22	72
31 Mar 25	-79	21	62
31 Dec 24	-71	20	56
30 Sep 24	-64	19	50
30 Jun 24	-62	18	50
31 Mar 24	-64	18	52
31 Dec 23	-64	17	52
30 Sep 23	-61	18	47
30 Jun 23	-55	17	41
31 Mar 23	-50	16	36
31 Dec 22	-38	17	35
30 Sep 22	-34	16	34
30 Jun 22	-25	15	32
31 Mar 22	-23	14	29
31 Dec 21	-31	11	25
30 Sep 21	-32	9	21
30 Jun 21	-39	8	19
31 Mar 21	-40	6	18
31 Dec 20	-32	5	16

Kaliteli Kazançlar: JSPR şu anda kârlı değil.

Büyüyen Kar Marjı: JSPR şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: JSPR kârlı değildir ve zararlar son 5 yılda yılda 20.8% oranında artmıştır.

Büyüme Hızlandırma: JSPR 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: JSPR kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 43% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: JSPR hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -1639.24% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/26 07:20
Gün Sonu Hisse Fiyatı	2026/05/26 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Jasper Therapeutics, Inc. 12 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Timothy Chiang	Capital One Securities, Inc.
Silvan Tuerkcan	Citizens JMP Securities, LLC
Gavin Clark-Gartner	Evercore ISI

Jasper Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

High number of new directors

High number of new directors

Jasper Therapeutics, Inc. Announces Executive Changes

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky

Price target decreased by 32% to US$12.33

New minor risk - Share price stability

Jasper Therapeutics, Inc. Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Jiangsu Jiangsu S.A. Announces Initial Results of Etesian Study

New major risk - Financial position

Price target increased by 10% to US$20.17

New major risk - Revenue and earnings growth

Rosen Law Firm Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

New major risk - Revenue and earnings growth

Price target decreased by 48% to US$25.11

Jasper Therapeutics, Inc. Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

New minor risk - Share price stability

Jasper Therapeutics, Inc.(NasdaqCM:JSPR) dropped from Russell 2500 Index

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Here's Why Jasper Therapeutics (NASDAQ:JSPR) Must Use Its Cash Wisely

Jasper Therapeutics, Inc., Annual General Meeting, Jul 03, 2025

New major risk - Financial position

Price target decreased by 8.2% to US$54.50

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Consensus EPS estimates fall by 17%

New major risk - Financial position

New major risk - Shareholder dilution

New minor risk - Market cap size

Price target decreased by 11% to US$61.44

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Jasper Therapeutics, Inc. Doses First Patient in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Jasper Therapeutics, Inc. Reports Positive Data from Spotlight Study of Briquilimab in Chronic Inducible Urticaria

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50.505 million.

New major risk - Share price stability

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.505 million.

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Price target decreased by 11% to US$61.25

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Less than half of directors are independent

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Price target increased by 9.8% to US$6.88

New major risk - Revenue and earnings growth

Jasper Therapeutics Strengthens Management Team with Key Appointments

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

CFO, COO & Corporate Secretary notifies of intention to sell stock

Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer

Jasper Therapeutics, Inc. Announces Appointment of Stephen J. Galli to Scientific Advisory Board

Jasper Therapeutics, Inc. Appoints Vishal Kapoor as Class I Director

Price target increased by 11% to US$5.97

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target decreased by 9.0% to US$7.10

Jasper Therapeutics, Inc. Announces New Positive Briquilimab Data to Be Presented at the 2023 Tandem Meetings

Jasper Therapeutics, Inc. Announces Development Prioritization of Briquilimab in Chronic Diseases

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as A Conditioning Treatment for Patients Prior to Receiving A Stem Cell Transplant

Jasper Therapeutics, Inc. Announces Positive Clinical Data from A Phase I/Ii Trial of Briquilimab as A Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Price target decreased to US$7.80